Cost-Effectiveness of Once-Weekly Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in the UK

被引：0
|
作者：
Muszbek, N. [1 ]
Angdembe, A. [1 ]
Garcia-Vidal, C. [2 ]
Bielicka, I [3 ]
Abrams, K. [1 ]
Tolley, K. [4 ]
Ruhnke, M. [5 ]
Lebmeier, M.
Hawkins, N. [1 ]
Manamley, N. [3 ]
Dickerson, S. [3 ]
机构：
[1] Visible Analyt, Oxford, Oxon, England
[2] Hosp Clin Barcelona, Barcelona, Catalonia, Spain
[3] Mundipharma Res Ltd, Cambridge, Cambs, England
[4] Tolley Hlth Econ, Buxton, DBY, England
[5] Helios Klinikum Aue, Aue Bad Schlema, Sachsen, Germany
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE332
引用
下载
收藏
页码：S115 / S115
页数：1
相关论文
共 50 条
  • [1] ONCE-WEEKLY REZAFUNGIN VERSUS DAILY CASPOFUNGIN TREATMENT OF CANDIDEMIA/ INVASIVE CANDIDIASIS
    Deresinski, Stan
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (10)
  • [2] Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
    Pierre Johansen
    Jonas Håkan-Bloch
    Aiden R. Liu
    Peter G. Bech
    Sofie Persson
    Lawrence A. Leiter
    PharmacoEconomics - Open, 2019, 3 : 537 - 550
  • [3] Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
    Johansen, Pierre
    Hakan-Bloch, Jonas
    Liu, Aiden R.
    Bech, Peter G.
    Persson, Sofie
    Leiter, Lawrence A.
    PHARMACOECONOMICS-OPEN, 2019, 3 (04) : 537 - 550
  • [4] An evaluation of Rezafungin: the latest treatment option for adults with candidemia and invasive candidiasis
    Sharma, Divisha
    Vazquez, Jose A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (04) : 339 - 347
  • [5] Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients
    Grau, S.
    Pozo, J. C.
    Roma, E.
    Salavert, M.
    Barrueta, J. A.
    Peral, C.
    Rodriguez, I.
    Rubio-Rodrguez, D.
    Rubio-Terres, C.
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2015, 7 : 527 - 535
  • [6] COST-EFFECTIVENESS ANALYSIS OF ONCE-WEEKLY SEMAGLUTIDE FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES IN MEXICO
    Valdez-Huerta, R.
    Moreno, D.
    Hernandez, Paladio J. A.
    VALUE IN HEALTH, 2022, 25 (07) : S429 - S429
  • [7] Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
    Johansen, Pierre
    Chubb, Barrie
    Hunt, Barnaby
    Malkin, Samuel J. P.
    Sandberg, Anna
    Capehorn, Matthew
    ADVANCES IN THERAPY, 2020, 37 (05) : 2427 - 2441
  • [8] Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
    Pierre Johansen
    Barrie Chubb
    Barnaby Hunt
    Samuel J. P. Malkin
    Anna Sandberg
    Matthew Capehorn
    Advances in Therapy, 2020, 37 : 2427 - 2441
  • [9] Regulatory Considerations in the Approval of Rezafungin (Rezzayo) for the Treatment of Candidemia and Invasive Candidiasis in Adults
    Smith, Heidi L.
    Bensman, Timothy J.
    Mishra, Shrimant
    Li, Xianbin
    Dixon, Cheryl A.
    Sheikh, Jalal
    McMaster, Owen G.
    Joshi, Abhay
    Rubin, Daniel B.
    Goodwin, Avery
    Miller, Terry J.
    Danielsen, Zhixia Y.
    Syed, Irum
    Shukla, Sunita J.
    Iarikov, Dmitri
    Kim, Peter W.
    Farley, John J.
    JOURNAL OF INFECTIOUS DISEASES, 2024, 230 (02): : 505 - 513
  • [10] THE COST-EFFECTIVENESS ANALYSIS OF ANIDULAFUNGIN VERSUS CASPOFUNGIN FOR CANDIDEMIA AND INVASIVE CANDIDIASIS TREATMENT: AN EXPERIENCE FROM IRAN
    Afzali, M.
    Zartab, S.
    Zaboli, P.
    Nikfar, S.
    Boorboor, M.
    VALUE IN HEALTH, 2018, 21 : S229 - S229
12345